Impact Biomedical (IBO) Other Accumulated Expenses (2023 - 2026)
Impact Biomedical's (IBO) quarterly Other Accumulated Expenses came in at $1.1 million in Q1 2026, up 77.62% on a QoQ basis from $621000.0 in Q4 2025.
Impact Biomedical (IBO) Other Accumulated Expenses (2023 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 4 years of Other Accumulated Expenses data on file, last reported at $1.1 million in Q1 2026.
- Quarterly Other Accumulated Expenses changed N/A year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (changed N/A YoY) and the FY2025 annual result came in at $621000.0, changed N/A from the prior year.
- Other Accumulated Expenses improved to $1.1 million in Q1 2026, from $621000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $1.1 million in Q1 2026 to a low of $152000.0 in Q1 2024.
- A 4-year average of $519000.0 and a median of $410500.0 in 2023 frame the typical range for Other Accumulated Expenses.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.33 Mn |
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | 621,000.00 |
| Mar 31, 2024 | 152,000.00 |
| Dec 31, 2023 | 200,000.00 |